References: |
Dibutyryl-cAMP inhibits neuronal glucose uptake via PKA activation. In cultured rat hepatocytes, Dibutyryl-cAMP inhibits inducible nitric oxide synthase expression and NF-kappaB-binding activity. Dibutyryl-cAMP also suppress TNFalpha-induced hepatocyte apoptosis by inhibiting FADD up-regulation. In a mouse model, bucladesine (600 nM/mouse, i.p.) reverses zinc chloride- and lead acetate-induced avoidance memory retention impairments. For the detailed information of Dibutyryl-cAMP (Bucladesine), the solubility of Dibutyryl-cAMP (Bucladesine) in water, the solubility of Dibutyryl-cAMP (Bucladesine) in DMSO, the solubility of Dibutyryl-cAMP (Bucladesine) in PBS buffer, the animal experiment (test) of Dibutyryl-cAMP (Bucladesine), the cell expriment (test) of Dibutyryl-cAMP (Bucladesine), the in vivo, in vitro and clinical trial test of Dibutyryl-cAMP (Bucladesine), the EC50, IC50,and affinity,of Dibutyryl-cAMP (Bucladesine), For the detailed information of Dibutyryl-cAMP (Bucladesine), the solubility of Dibutyryl-cAMP (Bucladesine) in water, the solubility of Dibutyryl-cAMP (Bucladesine) in DMSO, the solubility of Dibutyryl-cAMP (Bucladesine) in PBS buffer, the animal experiment (test) of Dibutyryl-cAMP (Bucladesine), the cell expriment (test) of Dibutyryl-cAMP (Bucladesine), the in vivo, in vitro and clinical trial test of Dibutyryl-cAMP (Bucladesine), the EC50, IC50,and affinity,of Dibutyryl-cAMP (Bucladesine), Please contact DC Chemicals. |